• 아이콘 LOCALLY SOURCED

    To find and license promising
    development candidates from
    domestic biotech/pharma
    companies and universities

  • 아이콘 REGIONALLY FINANCED

    To establish sources of financing
    from regional investment
    communities

  • 아이콘 GLOBALLY DEVELOPED

    To develop assets up to human
    PoC(Proof of Concept) globally

아이콘

Pipeline

We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.

이미지
아이콘

News

Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019

● The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers ● Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, presented results from Phase...

Read More

  • LEARN MORE ABOUT US
    페이스북 트위터 링크드인
  • CONTACT INFORMATION

    HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
    US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USA

    Director, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
    Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)